American Medical Technologies Inc. (ADLI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2007 | 479.63 Thousand USD | 43.53% |
| 2006 | 334.17 Thousand USD | -76.67% |
| 2005 | 1.43 Million USD | 211.77% |
| 2004 | 459.37 Thousand USD | -1.1% |
| 2003 | 464.47 Thousand USD | -73.69% |
| 2002 | 1.76 Million USD | 28.0% |
| 2001 | 1.37 Million USD | 45.16% |
| 2000 | 950.25 Thousand USD | -50.49% |
| 1999 | 1.91 Million USD | -57.73% |
| 1998 | 4.54 Million USD | 387.07% |
| 1997 | -1.58 Million USD | -116.02% |
| 1996 | -732.19 Thousand USD | -222.03% |
| 1995 | 600 Thousand USD | 200.0% |
| 1994 | 200 Thousand USD | 111.76% |
| 1993 | -1.7 Million USD | -240.0% |
| 1992 | -500 Thousand USD | 91.23% |
| 1991 | -5.7 Million USD | -400.0% |
| 1990 | 1.9 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2008 Q2 | 760.29 Thousand USD | 33.57% |
| 2008 Q3 | 753.29 Thousand USD | -0.92% |
| 2008 Q1 | 569.22 Thousand USD | 18.68% |
| 2007 Q4 | 479.63 Thousand USD | 21.67% |
| 2007 Q2 | 278.08 Thousand USD | -20.63% |
| 2007 FY | 479.63 Thousand USD | 43.53% |
| 2007 Q1 | 350.37 Thousand USD | 4.85% |
| 2007 Q3 | 394.2 Thousand USD | 41.76% |
| 2006 Q2 | 822.88 Thousand USD | -44.81% |
| 2006 Q3 | 405.05 Thousand USD | -50.78% |
| 2006 FY | 334.17 Thousand USD | -76.67% |
| 2006 Q4 | 334.17 Thousand USD | -17.5% |
| 2006 Q1 | 1.49 Million USD | 4.1% |
| 2005 Q2 | 1.12 Million USD | -12.85% |
| 2005 Q1 | 1.28 Million USD | 180.81% |
| 2005 FY | 1.43 Million USD | 211.77% |
| 2005 Q4 | 1.43 Million USD | 7.84% |
| 2005 Q3 | 1.32 Million USD | 18.13% |
| 2004 Q4 | 459.37 Thousand USD | 37.79% |
| 2004 Q2 | 668.05 Thousand USD | 197.54% |
| 2004 Q3 | 333.39 Thousand USD | -50.1% |
| 2004 Q1 | -684.87 Thousand USD | -247.45% |
| 2004 FY | 459.37 Thousand USD | -1.1% |
| 2003 Q1 | 1.94 Million USD | 9.96% |
| 2003 Q3 | -409.79 Thousand USD | -247.47% |
| 2003 Q4 | 464.47 Thousand USD | 213.34% |
| 2003 FY | 464.47 Thousand USD | -73.69% |
| 2003 Q2 | 277.87 Thousand USD | -85.69% |
| 2002 Q1 | 2.11 Million USD | 53.05% |
| 2002 Q2 | 1.95 Million USD | -7.58% |
| 2002 Q3 | 2.08 Million USD | 6.95% |
| 2002 Q4 | 1.76 Million USD | -15.39% |
| 2002 FY | 1.76 Million USD | 28.0% |
| 2001 Q2 | 905.75 Thousand USD | 126.98% |
| 2001 Q1 | 399.04 Thousand USD | -58.01% |
| 2001 Q3 | 1.56 Million USD | 73.22% |
| 2001 Q4 | 1.37 Million USD | -12.08% |
| 2001 FY | 1.37 Million USD | 45.16% |
| 2000 Q4 | 950.25 Thousand USD | -32.52% |
| 2000 Q1 | 2.77 Million USD | 44.49% |
| 2000 FY | 950.25 Thousand USD | -50.49% |
| 2000 Q2 | 2.75 Million USD | -0.82% |
| 2000 Q3 | 1.4 Million USD | -48.8% |
| 1999 Q1 | 4.84 Million USD | 6.64% |
| 1999 Q4 | 1.91 Million USD | -57.96% |
| 1999 Q3 | 4.56 Million USD | 16.91% |
| 1999 Q2 | 3.9 Million USD | -19.34% |
| 1999 FY | 1.91 Million USD | -57.73% |
| 1998 Q1 | -2.26 Million USD | -43.43% |
| 1998 FY | 4.54 Million USD | 387.07% |
| 1998 Q4 | 4.54 Million USD | 17.4% |
| 1998 Q3 | 3.86 Million USD | 202.3% |
| 1998 Q2 | -3.78 Million USD | -66.64% |
| 1997 Q3 | -1.61 Million USD | 18.28% |
| 1997 FY | -1.58 Million USD | -116.02% |
| 1997 Q4 | -1.58 Million USD | 1.83% |
| 1997 Q2 | -1.97 Million USD | -73.33% |
| 1997 Q1 | -1.13 Million USD | -55.35% |
| 1996 Q3 | -1.06 Million USD | -184.44% |
| 1996 Q4 | -732.19 Thousand USD | 31.3% |
| 1996 FY | -732.19 Thousand USD | -222.03% |
| 1996 Q2 | 1.26 Million USD | 5.19% |
| 1996 Q1 | 1.2 Million USD | 100.0% |
| 1995 FY | 600 Thousand USD | 200.0% |
| 1995 Q4 | 600 Thousand USD | 300.0% |
| 1995 Q1 | -200 Thousand USD | -200.0% |
| 1995 Q2 | 300 Thousand USD | 250.0% |
| 1995 Q3 | -300 Thousand USD | -200.0% |
| 1994 Q4 | 200 Thousand USD | 140.0% |
| 1994 Q2 | -1 Million USD | -400.0% |
| 1994 Q1 | -200 Thousand USD | 88.24% |
| 1994 Q3 | -500 Thousand USD | 50.0% |
| 1994 FY | 200 Thousand USD | 111.76% |
| 1993 Q4 | -1.7 Million USD | -70.0% |
| 1993 FY | -1.7 Million USD | -240.0% |
| 1993 Q1 | -1 Million USD | -100.0% |
| 1993 Q2 | -1.8 Million USD | -80.0% |
| 1993 Q3 | -1 Million USD | 44.44% |
| 1992 Q2 | -2.1 Million USD | 0.0% |
| 1992 Q3 | -1.5 Million USD | 28.57% |
| 1992 Q4 | -500 Thousand USD | 66.67% |
| 1992 FY | -500 Thousand USD | 91.23% |
| 1992 Q1 | -2.1 Million USD | 63.16% |
| 1991 FY | -5.7 Million USD | -400.0% |
| 1991 Q1 | 2 Million USD | 5.26% |
| 1991 Q2 | -8.1 Million USD | -505.0% |
| 1991 Q4 | -5.7 Million USD | 14.93% |
| 1991 Q3 | -6.7 Million USD | 17.28% |
| 1990 Q4 | 1.9 Million USD | 0.0% |
| 1990 FY | 1.9 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Ansell Limited | -54.99 Million USD | 100.872% |
| Ansell Limited | -55.1 Million USD | 100.87% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | -36.49 Million USD | 101.314% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -105.1 Thousand USD | 556.348% |
| Psykey, Inc. | 634.59 Thousand USD | 24.419% |
| ConvaTec Group Plc | 1.2 Billion USD | 99.96% |
| ConvaTec Group Plc | 1.2 Billion USD | 99.96% |
| Encision Inc. | 1.29 Million USD | 62.839% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 2.3 Million USD | 79.225% |
| Innovative MedTech Inc. | 1.76 Million USD | 72.821% |
| LifePoint, Inc. | -3.26 Million USD | 114.694% |
| Medite Cancer Diagnostics, Inc. | 4.9 Million USD | 90.22% |
| Paradigm Medical Industries, Inc. | 2.16 Million USD | 77.815% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -43.3 Thousand USD | 1207.591% |
| Reflect Scientific, Inc. | -1.03 Million USD | 146.327% |
| SmileDirectClub, Inc. | 778.67 Million USD | 99.938% |
| Sector 10, Inc. | 163 Thousand USD | -194.252% |
| Shandong Weigao Group Medical Polymer Company Limited | -417.55 Million USD | 100.115% |
| SheerVision, Inc. | 57.34 Thousand USD | -736.337% |
| United Health Products, Inc. | 660.56 Thousand USD | 27.391% |
| Vasamed, Inc. | 22.12 Thousand USD | -2068.118% |
| Wearable Health Solutions, Inc. | 2.63 Million USD | 81.772% |
| Yubo International Biotech Limited | 772.27 Thousand USD | 37.894% |